Giant cell tumor of bone (GCTB) is a rare osteolytic bone tumor, accounting for approximately 5% of all primary bone tumors. GCTB is characterized by unique giant cells. It is also characterized by recurrent mutations in the histone tail of the histone variant H3.3, H3F3A, on chromosome 1, therapeutic implications of which have not been established yet. There are few effective standardized treatments for GCTB, and a novel therapy has long been required. Patient-derived cancer cells have facilitated the understanding of mechanisms underlying the etiology and progression of multiple cancers. Thus far, only 10 GCTB cell lines have been reported, and none of them are publicly available. The aim of this study was to develop an accessible patient-derived cell line of GCTB, which could be used as a screening tool for drug development. Here, we describe the establishment of a cell line, designated NCC-GCTB1-C1, from the primary tumor tissue of a male patient with GCTB on the right distal radius. NCC-GCTB1-C1 cells were maintained as a monolayer culture for over 23 passages for 7 months. These cells exhibited continuous growth, as well as spheroid formation and invasive ability. Using an oncology agent screen, we tested the effect of anticancer drugs on the proliferation of NCC-GCTB1-C1 cells. The cells displayed a remarkable response to romidepsin and vincristine. Thus, we established a novel GCTB cell line, NCC-GCTB1-C1, which could be a useful tool for studying GCTB tumorigenesis and the efficacy of anticancer drugs.

骨巨细胞瘤（GCTB）是一种罕见的溶骨性骨肿瘤，约占所有原发性骨肿瘤的5％。GCTB的特征在于独特的巨细胞。其特征还在于组蛋白变体H3.3，H3F3A的组蛋白尾巴中发生反复突变在1号染色体上，尚无治疗意义。对于GCTB几乎没有有效的标准化治疗方法，长期以来一直需要一种新颖的治疗方法。患者来源的癌细胞促进了对多种癌症的病因和进展的潜在机制的理解。迄今为止，仅报道了10个GCTB细胞系，但均未公开。这项研究的目的是开发一种可利用的患者来源的GCTB细胞系，该细胞系可用作药物开发的筛选工具。在这里，我们描述了从男性远端右侧radius骨GCTB的原发肿瘤组织中建立的细胞系，命名为NCC-GCTB1-C1。将NCC-GCTB1-C1细胞作为单层培养物维持23代以上，持续7个月。这些细胞表现出连续的生长，以及球体的形成和侵袭能力。使用肿瘤药物筛选，我们测试了抗癌药对NCC-GCTB1-C1细胞增殖的影响。细胞显示出对罗米地辛和长春新碱的显着反应。因此，我们建立了新的GCTB细胞系NCC-GCTB1-C1，该细胞系可能是研究GCTB肿瘤发生和抗癌药功效的有用工具。